143 related articles for article (PubMed ID: 32144652)
1. Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis.
Darbà J
Clin Drug Investig; 2020 Apr; 40(4):335-341. PubMed ID: 32144652
[TBL] [Abstract][Full Text] [Related]
2. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis.
Darbà J; Marsà A
BMJ Open; 2019 Nov; 9(11):e031271. PubMed ID: 31753879
[TBL] [Abstract][Full Text] [Related]
3. Management and current status of spinal muscular atrophy: a retrospective multicentre claims database analysis.
Darbà J
Orphanet J Rare Dis; 2020 Jan; 15(1):8. PubMed ID: 31924248
[TBL] [Abstract][Full Text] [Related]
4. Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
Paracha N; Hudson P; Mitchell S; Sutherland CS
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):11-38. PubMed ID: 34761360
[TBL] [Abstract][Full Text] [Related]
5. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain.
López-Bastida J; Peña-Longobardo LM; Aranda-Reneo I; Tizzano E; Sefton M; Oliva-Moreno J
Orphanet J Rare Dis; 2017 Aug; 12(1):141. PubMed ID: 28821278
[TBL] [Abstract][Full Text] [Related]
6. Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis.
Darbà J
PLoS One; 2019; 14(10):e0223772. PubMed ID: 31603947
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada.
Chen G; Sharif B; Gerber B; Farris MS; Cowling T; Cabalteja C; Wu JW; Maturi B; Klein-Panneton K; Jean K Mah
J Med Econ; 2021 Nov; 24(sup1):51-59. PubMed ID: 34906030
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Adult Patients With SMA Treated in US Hospital Settings: A Natural History Study in the Premier Healthcare Database.
Johnson NB; Proud C; Wassel CL; Dreyfus J; Cochrane T; Paradis AD
J Neuromuscul Dis; 2021; 8(4):569-578. PubMed ID: 33843692
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of spinal muscular atrophy.
Armstrong EP; Malone DC; Yeh WS; Dahl GJ; Lee RL; Sicignano N
J Med Econ; 2016 Aug; 19(8):822-6. PubMed ID: 27264163
[TBL] [Abstract][Full Text] [Related]
10. Characteristics, management and medical costs of patients with depressive disorders admitted in primary and specialised care centres in Spain between 2011 and 2016.
Darbà J; Marsà A
PLoS One; 2020; 15(2):e0228749. PubMed ID: 32023308
[TBL] [Abstract][Full Text] [Related]
11. Disease burden of spinal muscular atrophy in Germany.
Klug C; Schreiber-Katz O; Thiele S; Schorling E; Zowe J; Reilich P; Walter MC; Nagels KH
Orphanet J Rare Dis; 2016 May; 11(1):58. PubMed ID: 27145956
[TBL] [Abstract][Full Text] [Related]
12. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data.
Chan SHS; Wong CKH; Wu T; Wong W; Yu MKL; Au ICH; Chan GCF
Eur J Health Econ; 2023 Nov; 24(8):1373-1382. PubMed ID: 36403177
[TBL] [Abstract][Full Text] [Related]
13. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy.
Lee M; França UL; Graham RJ; McManus ML
Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237
[No Abstract] [Full Text] [Related]
14. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
15. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
16. Characteristics, comorbidities, and use of healthcare resources of patients with phenylketonuria: a population-based study.
Darbà J
J Med Econ; 2019 Oct; 22(10):1025-1029. PubMed ID: 31237171
[No Abstract] [Full Text] [Related]
17. Costs of Illness of Spinal Muscular Atrophy: A Systematic Review.
Landfeldt E; Pechmann A; McMillan HJ; Lochmüller H; Sejersen T
Appl Health Econ Health Policy; 2021 Jul; 19(4):501-520. PubMed ID: 33576939
[TBL] [Abstract][Full Text] [Related]
18. Direct costs of both inpatient and outpatient care for all type cancers: The evidence from Beijing, China.
Yin X; Xu Y; Man X; Liu L; Jiang Y; Zhao L; Cheng W
Cancer Med; 2019 Jun; 8(6):3250-3260. PubMed ID: 31062522
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
Pacione M; Siskind CE; Day JW; Tabor HK
J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
[TBL] [Abstract][Full Text] [Related]
20. The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe.
Peña-Longobardo LM; Aranda-Reneo I; Oliva-Moreno J; Litzkendorf S; Durand-Zaleski I; Tizzano E; López-Bastida J
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32764338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
